Caribou Biosciences (NASDAQ:CRBU – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01, Zacks reports. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million.
Caribou Biosciences Price Performance
CRBU opened at $1.11 on Tuesday. The company’s 50 day simple moving average is $1.42 and its two-hundred day simple moving average is $1.81. Caribou Biosciences has a 1-year low of $1.01 and a 1-year high of $7.61. The firm has a market capitalization of $100.06 million, a price-to-earnings ratio of -0.67 and a beta of 2.34.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on CRBU. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Citigroup cut their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Finally, Bank of America cut their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $10.33.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Caribou Biosciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential
- How to Invest in the FAANG Stocks
- Costco Price Plunge Equals Opportunity for Investors
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks Investing $650 Billion in the U.S.—Should You Invest?
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
